title: Correlation between beta1 integrin expression and prognosis in clinically localized prostate cancer.
abstract: Integrins are transmembrane glycoprotein receptors that regulate cell-matrix interactions, thus functioning as sensors from the environment. They also act as cell adhesion molecules that are responsible for the maintenance of the normal epithelial phenotype. Some studies have reported a correlation between carcinogenesis and changes in integrin expression, especially β1 integrin, however its role in prostate cancer (PC) is unclear. The aim of our study was to evaluate the expression of β1 integrin in localized PC and to correlate the pattern of expression with recurrence after surgical treatment. Methods For this case-control study, we retrospectively selected surgical specimens from 111 patients with localized PC who underwent radical prostatectomy. Recurrence was defined as a PSA level exceeding 0.2 ng/mL after surgery, and the median follow-up was 123 months. Integrin expression was evaluated by immunohistochemistry in a tissue microarray containing two samples from each tumor. We employed a semiquantitative analysis and considered a case as positive when the expression was strong and diffusely present.
  
  
  RESULTS
  There was a loss of 11 cases during the tissue micro array assembling. β1 expression was positive in 79 of the 100 evaluated cases (79%). The univariate and multivariate analyses showed that the negative expression of β1 integrin was associated with biochemical recurrence (p = 0.047) and time to recurrence after radical prostatectomy (p = 0.023). When β1 was negative, the odds ratio for recurrence was 2.78 times higher than that observed in the positive cases [OR = 2.78, p = 0.047, IC 95% (1.01-7.66)].
  
  
  CONCLUSIONS
  The loss of β1 integrin immune expression was correlated with biochemical recurrence in patients treated with radical prostatectomy for localized PC.
authors.affiliation: Laboratory of Medical Investigation - LIM 55, Urology Department, University of Sao Paulo Medical, School and Universidade Nove de Julho, Sao Paulo, Brazil.
authors.forename: José
authors.initials: J
authors.lastname: Pontes-Júnior
authors.forename: Sabrina Thalita
authors.initials: ST
authors.lastname: Reis
authors.forename: Felipe S
authors.initials: FS
authors.lastname: Bernardes
authors.forename: Luiz C N
authors.initials: LC
authors.lastname: Oliveira
authors.forename: Érika Aparecida Felix de
authors.initials: ÉA
authors.lastname: Barros
authors.forename: Marcos Francisco
authors.initials: MF
authors.lastname: Dall'Oglio
authors.forename: Luciana M S
authors.initials: LM
authors.lastname: Timosczuk
authors.forename: Leopoldo A
authors.initials: LA
authors.lastname: Ribeiro-Filho
authors.forename: Miguel
authors.initials: M
authors.lastname: Srougi
authors.forename: Katia R M
authors.initials: KR
authors.lastname: Leite
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D019012:Integrin beta1 / Q000032:analysis*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000737:chemistry* / Q000473:pathology; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000473:pathology; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D019012:Integrin beta1; D017430:Prostate-Specific Antigen